Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320632 · ClinicalTrials.gov registry record · Phase 4
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
A Phase 4 study, sponsored by Harvard Medical School (HMS and HSDM).
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT00320632: Completed Phase 4 study, sponsored by Harvard Medical School (HMS and HSDM).
NCT00320632 is a Phase 4 study that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00320632, a Phase 4 study, has completed, sponsored by Harvard Medical School (HMS and HSDM).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).
Interventions
- DRUG Desipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1990-08 |
| Est. Completion | 1993-07 |
| Phase | Phase 4 |
What the finished NCT00320632 record still lists
NCT00320632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Desipramine is the first listed.
NCT00320632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00320632 about?
NCT00320632 is a clinical study titled "Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression". This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).
What is the current status of trial NCT00320632?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 1990-08. Estimated completion is 1993-07.
What interventions are being tested in trial NCT00320632?
The interventions under investigation include: Desipramine (DRUG).
Who is sponsoring clinical trial NCT00320632?
This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00320632's enrollment target sits among peer trials
43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia